Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | What to look forward to in GU at ESMO 2022?

Michiel Strijbos • 9 Sep 2022
ESMO 2022
Genitourinary Cancer Kidney Cancer Antibodies Ipilimumab Nivolumab

Michiel Strijbos, MD, GasthuisZusters Antwerpen, Antwerp, Belgium, discusses updates in genitourinary cancers to look forward to at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France, including data on the use of adjuvant ipilimumab and nivolumab in localized kidney cancer which may prove to be practice changing. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

More from Michiel Strijbos

1:12
The rise of de-escalation strategies in cancer care
Michiel Strijbos • 9 Sep 2022
2:01
The fundamentals of de-escalation in oncology
Michiel Strijbos • 9 Sep 2022

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals